CA3077509A1 - Ctla-4 variant immunomodulatory proteins and uses thereof - Google Patents
Ctla-4 variant immunomodulatory proteins and uses thereof Download PDFInfo
- Publication number
- CA3077509A1 CA3077509A1 CA3077509A CA3077509A CA3077509A1 CA 3077509 A1 CA3077509 A1 CA 3077509A1 CA 3077509 A CA3077509 A CA 3077509A CA 3077509 A CA3077509 A CA 3077509A CA 3077509 A1 CA3077509 A1 CA 3077509A1
- Authority
- CA
- Canada
- Prior art keywords
- polypeptide
- ctla
- domain
- variant
- variant ctla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 101
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 101
- 230000002519 immonomodulatory effect Effects 0.000 title claims abstract description 92
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims abstract description 322
- 229940045513 CTLA4 antagonist Drugs 0.000 claims abstract description 321
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 284
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 281
- 229920001184 polypeptide Polymers 0.000 claims abstract description 280
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims abstract description 158
- 238000000034 method Methods 0.000 claims abstract description 42
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 22
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 22
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 22
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 230000001363 autoimmune Effects 0.000 claims abstract description 17
- 102220344288 rs1554032090 Human genes 0.000 claims description 880
- 102200101766 rs72554324 Human genes 0.000 claims description 682
- 102220119533 rs375389609 Human genes 0.000 claims description 503
- 102220032940 rs367543239 Human genes 0.000 claims description 349
- 102220350613 c.214A>G Human genes 0.000 claims description 283
- 102200118258 rs35094013 Human genes 0.000 claims description 188
- 102220005270 rs33932981 Human genes 0.000 claims description 183
- 102220195869 rs751437780 Human genes 0.000 claims description 158
- 102220286033 rs1553301271 Human genes 0.000 claims description 153
- 150000001413 amino acids Chemical class 0.000 claims description 145
- 102220133301 rs757905542 Human genes 0.000 claims description 133
- 230000004048 modification Effects 0.000 claims description 106
- 238000012986 modification Methods 0.000 claims description 106
- 210000004027 cell Anatomy 0.000 claims description 99
- 230000027455 binding Effects 0.000 claims description 91
- 102220218217 rs1060502513 Human genes 0.000 claims description 84
- 102220251295 rs1555027633 Human genes 0.000 claims description 72
- 102200025123 rs145047094 Human genes 0.000 claims description 67
- 102200101764 rs72554320 Human genes 0.000 claims description 60
- 102200113220 rs35220041 Human genes 0.000 claims description 57
- 102220011706 rs201343342 Human genes 0.000 claims description 50
- 102200135024 rs35877720 Human genes 0.000 claims description 49
- 230000009870 specific binding Effects 0.000 claims description 46
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims description 44
- 102220227032 rs1064793026 Human genes 0.000 claims description 44
- 239000012634 fragment Substances 0.000 claims description 43
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 42
- 102200121805 rs1085307185 Human genes 0.000 claims description 42
- 102220024983 rs199473649 Human genes 0.000 claims description 42
- 102100034980 ICOS ligand Human genes 0.000 claims description 41
- 102200088402 rs121908653 Human genes 0.000 claims description 39
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 37
- 230000001086 cytosolic effect Effects 0.000 claims description 36
- 230000001965 increasing effect Effects 0.000 claims description 36
- 102220022283 rs397509331 Human genes 0.000 claims description 36
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 33
- 102220222503 rs751802145 Human genes 0.000 claims description 33
- 102220005154 rs33988732 Human genes 0.000 claims description 32
- 102220011021 rs397507516 Human genes 0.000 claims description 30
- 102220316328 rs1315405264 Human genes 0.000 claims description 28
- 102220098555 rs878853237 Human genes 0.000 claims description 28
- 102220278973 rs1554708772 Human genes 0.000 claims description 26
- 102220005411 rs35873730 Human genes 0.000 claims description 26
- 230000028993 immune response Effects 0.000 claims description 24
- 102220340761 rs1052030 Human genes 0.000 claims description 24
- 238000006467 substitution reaction Methods 0.000 claims description 24
- 230000011664 signaling Effects 0.000 claims description 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
- 102200096038 rs386834125 Human genes 0.000 claims description 22
- 102220344286 rs1554032090 Human genes 0.000 claims description 20
- 102220579491 Transthyretin_T69I_mutation Human genes 0.000 claims description 18
- 102200029469 rs63750123 Human genes 0.000 claims description 18
- 108091008874 T cell receptors Proteins 0.000 claims description 17
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 17
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 16
- 102220578417 Transthyretin_I93V_mutation Human genes 0.000 claims description 16
- 102200115907 rs121918081 Human genes 0.000 claims description 16
- 102200163544 rs63750792 Human genes 0.000 claims description 16
- 102220561101 5'-AMP-activated protein kinase subunit gamma-1_T89S_mutation Human genes 0.000 claims description 15
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 15
- 230000002757 inflammatory effect Effects 0.000 claims description 15
- 102220040807 rs111826855 Human genes 0.000 claims description 14
- 102220155715 rs886062788 Human genes 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 239000013598 vector Substances 0.000 claims description 13
- 102220557008 F-box/LRR-repeat protein 12_L63H_mutation Human genes 0.000 claims description 12
- 102220473085 HLA class II histocompatibility antigen, DP alpha 1 chain_A42T_mutation Human genes 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 102220415904 c.104G>A Human genes 0.000 claims description 12
- 239000012636 effector Substances 0.000 claims description 12
- 230000006870 function Effects 0.000 claims description 12
- 102200017779 rs10132601 Human genes 0.000 claims description 12
- 102220036548 rs140382474 Human genes 0.000 claims description 12
- 102200003634 rs199696526 Human genes 0.000 claims description 12
- 102200046979 rs62645879 Human genes 0.000 claims description 12
- 102220149729 rs763469367 Human genes 0.000 claims description 12
- 102220073946 rs778958318 Human genes 0.000 claims description 12
- 102220143226 rs886058292 Human genes 0.000 claims description 12
- 208000023275 Autoimmune disease Diseases 0.000 claims description 11
- 230000004068 intracellular signaling Effects 0.000 claims description 11
- 102200155004 rs62619924 Human genes 0.000 claims description 11
- 210000001519 tissue Anatomy 0.000 claims description 11
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 10
- 102220408680 c.200T>C Human genes 0.000 claims description 10
- 102220173399 rs146534475 Human genes 0.000 claims description 10
- 102220077594 rs761906487 Human genes 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 102200031581 rs864309650 Human genes 0.000 claims description 9
- 102220519818 Glutathione synthetase_A26D_mutation Human genes 0.000 claims description 8
- 230000007423 decrease Effects 0.000 claims description 8
- 102000043321 human CTLA4 Human genes 0.000 claims description 8
- 210000002865 immune cell Anatomy 0.000 claims description 8
- 210000004698 lymphocyte Anatomy 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 102200156918 rs387906512 Human genes 0.000 claims description 8
- 102220044832 rs587781608 Human genes 0.000 claims description 8
- 102200008483 rs74315401 Human genes 0.000 claims description 8
- 102220627364 Dolichyl pyrophosphate Man9GlcNAc2 alpha-1,3-glucosyltransferase_A42S_mutation Human genes 0.000 claims description 7
- 239000012678 infectious agent Substances 0.000 claims description 7
- 210000004962 mammalian cell Anatomy 0.000 claims description 7
- 102220596352 CUGBP Elav-like family member 1_L12I_mutation Human genes 0.000 claims description 6
- 102220472254 Eukaryotic translation initiation factor 4E transporter_Y54F_mutation Human genes 0.000 claims description 6
- 206010047115 Vasculitis Diseases 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 102200159386 rs60798368 Human genes 0.000 claims description 6
- 230000008685 targeting Effects 0.000 claims description 6
- 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 claims description 5
- 108010074328 Interferon-gamma Proteins 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 239000000833 heterodimer Substances 0.000 claims description 5
- 102000054189 human CD80 Human genes 0.000 claims description 5
- 102000049849 human CD86 Human genes 0.000 claims description 5
- 102000046492 human ICOSLG Human genes 0.000 claims description 5
- 230000003834 intracellular effect Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 102220265087 rs1554817350 Human genes 0.000 claims description 5
- 102220328919 rs1555631387 Human genes 0.000 claims description 5
- 102220610050 Chromogranin-A_M56L_mutation Human genes 0.000 claims description 4
- 102220622722 G protein-coupled receptor kinase 5_Q41L_mutation Human genes 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 4
- 102220587467 Protein FAM102A_M87A_mutation Human genes 0.000 claims description 4
- 102220616555 S-phase kinase-associated protein 2_E48R_mutation Human genes 0.000 claims description 4
- 102220483110 TLC domain-containing protein 4_N75D_mutation Human genes 0.000 claims description 4
- 102220475444 Vacuolar protein sorting-associated protein 33A_V22A_mutation Human genes 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 239000000710 homodimer Substances 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- 229960003130 interferon gamma Drugs 0.000 claims description 4
- 210000003289 regulatory T cell Anatomy 0.000 claims description 4
- 102220006123 rs1042713 Human genes 0.000 claims description 4
- 102200071072 rs104893972 Human genes 0.000 claims description 4
- 102220068644 rs150880478 Human genes 0.000 claims description 4
- 102220005450 rs33939620 Human genes 0.000 claims description 4
- 102200082931 rs33945546 Human genes 0.000 claims description 4
- 102220217675 rs370859268 Human genes 0.000 claims description 4
- 102220094031 rs777491507 Human genes 0.000 claims description 4
- 102220250575 rs900324585 Human genes 0.000 claims description 4
- 102220596745 Gap junction alpha-1 protein_S27P_mutation Human genes 0.000 claims description 3
- 102220573173 Magnesium transporter NIPA4_S73R_mutation Human genes 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 210000004986 primary T-cell Anatomy 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 102220318854 rs1554258810 Human genes 0.000 claims description 3
- 102220041129 rs529720410 Human genes 0.000 claims description 3
- 102200134465 rs80338876 Human genes 0.000 claims description 3
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 208000004300 Atrophic Gastritis Diseases 0.000 claims description 2
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 208000006373 Bell palsy Diseases 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010011878 Deafness Diseases 0.000 claims description 2
- 208000016192 Demyelinating disease Diseases 0.000 claims description 2
- 201000003066 Diffuse Scleroderma Diseases 0.000 claims description 2
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 2
- 208000017701 Endocrine disease Diseases 0.000 claims description 2
- 208000036495 Gastritis atrophic Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- 206010066476 Haematological malignancy Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- 206010058359 Hypogonadism Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 206010028665 Myxoedema Diseases 0.000 claims description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 241000721454 Pemphigus Species 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010037549 Purpura Diseases 0.000 claims description 2
- 241001672981 Purpura Species 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000025747 Rheumatic disease Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000034189 Sclerosis Diseases 0.000 claims description 2
- 208000032384 Severe immune-mediated enteropathy Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 208000000277 Splenic Neoplasms Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 2
- 206010043784 Thyroiditis subacute Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 208000004631 alopecia areata Diseases 0.000 claims description 2
- 230000001977 ataxic effect Effects 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 208000037896 autoimmune cutaneous disease Diseases 0.000 claims description 2
- 208000001974 autoimmune enteropathy Diseases 0.000 claims description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 201000010064 diabetes insipidus Diseases 0.000 claims description 2
- 208000010643 digestive system disease Diseases 0.000 claims description 2
- 239000000539 dimer Substances 0.000 claims description 2
- 201000002491 encephalomyelitis Diseases 0.000 claims description 2
- 230000002124 endocrine Effects 0.000 claims description 2
- 208000030172 endocrine system disease Diseases 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000010749 gastric carcinoma Diseases 0.000 claims description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 2
- 201000003115 germ cell cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 230000010370 hearing loss Effects 0.000 claims description 2
- 231100000888 hearing loss Toxicity 0.000 claims description 2
- 208000016354 hearing loss disease Diseases 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 2
- 208000007475 hemolytic anemia Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 208000000509 infertility Diseases 0.000 claims description 2
- 230000036512 infertility Effects 0.000 claims description 2
- 231100000535 infertility Toxicity 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 208000003786 myxedema Diseases 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 2
- 201000005737 orchitis Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 102220101582 rs74555599 Human genes 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 201000002471 spleen cancer Diseases 0.000 claims description 2
- 230000003393 splenic effect Effects 0.000 claims description 2
- 201000000498 stomach carcinoma Diseases 0.000 claims description 2
- 230000002889 sympathetic effect Effects 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 230000002446 thrombocytic effect Effects 0.000 claims description 2
- 206010043778 thyroiditis Diseases 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 208000009174 transverse myelitis Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 102220026629 rs587778901 Human genes 0.000 claims 18
- 102220345529 c.192C>G Human genes 0.000 claims 7
- 102220319450 rs1554378297 Human genes 0.000 claims 7
- 102220064253 rs779277447 Human genes 0.000 claims 6
- 102200068713 rs281865218 Human genes 0.000 claims 3
- 102220484369 E3 ubiquitin-protein ligase RNF168_I18A_mutation Human genes 0.000 claims 2
- 102220474763 HLA class II histocompatibility antigen, DP alpha 1 chain_E59D_mutation Human genes 0.000 claims 2
- 102100037850 Interferon gamma Human genes 0.000 claims 2
- 102220624790 Non-structural maintenance of chromosomes element 4 homolog A_S72T_mutation Human genes 0.000 claims 2
- 102100035071 Vimentin Human genes 0.000 claims 2
- 102220353742 c.41G>A Human genes 0.000 claims 2
- 102220323601 rs1555225091 Human genes 0.000 claims 2
- 102100031491 Arylsulfatase B Human genes 0.000 claims 1
- 102220370670 c.247G>A Human genes 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 4
- 230000004968 inflammatory condition Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 166
- 235000001014 amino acid Nutrition 0.000 description 91
- 229940024606 amino acid Drugs 0.000 description 80
- 235000018102 proteins Nutrition 0.000 description 56
- 239000003446 ligand Substances 0.000 description 20
- 102220473080 HLA class II histocompatibility antigen, DP alpha 1 chain_A42V_mutation Human genes 0.000 description 18
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 14
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 14
- 230000000139 costimulatory effect Effects 0.000 description 12
- 230000006044 T cell activation Effects 0.000 description 11
- 230000003213 activating effect Effects 0.000 description 9
- 230000003993 interaction Effects 0.000 description 8
- 102220607933 C-reactive protein_E59K_mutation Human genes 0.000 description 7
- 102100021317 Inducible T-cell costimulator Human genes 0.000 description 7
- 101710205775 Inducible T-cell costimulator Proteins 0.000 description 7
- 108091008034 costimulatory receptors Proteins 0.000 description 7
- 102220128858 rs200860772 Human genes 0.000 description 7
- 210000000428 immunological synapse Anatomy 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000009386 Experimental Arthritis Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 238000001994 activation Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000016396 cytokine production Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 229960003697 abatacept Drugs 0.000 description 3
- 230000005784 autoimmunity Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
- 101710093458 ICOS ligand Proteins 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 230000010799 Receptor Interactions Effects 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 229960005347 belatacept Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 102220214161 rs1060501307 Human genes 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 102220508069 5'-3' exoribonuclease 1_G4S_mutation Human genes 0.000 description 1
- 102220646192 Actin-like protein 7A_A31Y_mutation Human genes 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- -1 CD86 Proteins 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- XQLBWXHVZVBNJM-FXQIFTODSA-N Pro-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 XQLBWXHVZVBNJM-FXQIFTODSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 230000033540 T cell apoptotic process Effects 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000015861 cell surface binding Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000006237 glutamylation Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 230000007896 negative regulation of T cell activation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3198255A CA3198255A1 (en) | 2017-10-10 | 2018-10-09 | Ctla-4 variant immunomodulatory proteins and uses thereof |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570619P | 2017-10-10 | 2017-10-10 | |
| US62/570,619 | 2017-10-10 | ||
| US201862613379P | 2018-01-03 | 2018-01-03 | |
| US62/613,379 | 2018-01-03 | ||
| US201862733615P | 2018-09-19 | 2018-09-19 | |
| US62/733,615 | 2018-09-19 | ||
| PCT/US2018/055095 WO2019074983A1 (en) | 2017-10-10 | 2018-10-09 | CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3198255A Division CA3198255A1 (en) | 2017-10-10 | 2018-10-09 | Ctla-4 variant immunomodulatory proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3077509A1 true CA3077509A1 (en) | 2019-04-18 |
Family
ID=63966157
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3077509A Pending CA3077509A1 (en) | 2017-10-10 | 2018-10-09 | Ctla-4 variant immunomodulatory proteins and uses thereof |
| CA3198255A Pending CA3198255A1 (en) | 2017-10-10 | 2018-10-09 | Ctla-4 variant immunomodulatory proteins and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3198255A Pending CA3198255A1 (en) | 2017-10-10 | 2018-10-09 | Ctla-4 variant immunomodulatory proteins and uses thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11753458B2 (enExample) |
| EP (3) | EP3694870A1 (enExample) |
| JP (3) | JP7749319B2 (enExample) |
| KR (3) | KR102813968B1 (enExample) |
| CN (2) | CN111801347A (enExample) |
| CA (2) | CA3077509A1 (enExample) |
| MA (1) | MA50360A (enExample) |
| WO (1) | WO2019074983A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11274140B2 (en) | 2020-05-08 | 2022-03-15 | Alpine Immune Sciences, Inc. | APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3283508B1 (en) | 2015-04-17 | 2021-03-17 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| KR102813968B1 (ko) | 2017-10-10 | 2025-05-29 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| EP3735417A1 (en) | 2018-01-03 | 2020-11-11 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| CN112638419B (zh) * | 2018-11-02 | 2022-06-24 | 北京伟德杰生物科技有限公司 | 修饰的ctla4及其使用方法 |
| JP7650047B2 (ja) * | 2019-11-27 | 2025-03-24 | 株式会社 MiyaCare Therapeutics | 変異型結合性タンパク質の製造方法及び変異型ｐｄ－１ |
| CN111592580A (zh) * | 2020-05-08 | 2020-08-28 | 中国药科大学 | 一种具有免疫检查点ctla-4抑制活性的多肽及其应用 |
| WO2023205796A2 (en) * | 2022-04-21 | 2023-10-26 | Ohio State Innovation Foundation | Human ctla-4 peptide vaccines and uses thereof |
| CN119679395B (zh) * | 2024-12-04 | 2025-09-23 | 山东大学 | 一种基于动力学图融合的腺样体肥大辅助检测系统及方法 |
Family Cites Families (175)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5443964A (en) | 1987-08-10 | 1995-08-22 | Duke University | Poxvirus insertion/expression vector |
| US6218525B1 (en) | 1988-02-25 | 2001-04-17 | The General Hospital Corporation | Nucleic acid encoding CD28 |
| US6685941B1 (en) | 1988-11-23 | 2004-02-03 | The Regents Of The University Of Michigan | Methods of treating autoimmune disease via CTLA-4Ig |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| WO1992019266A1 (en) | 1991-05-06 | 1992-11-12 | The United States Of America, As Represented By The Department Of Health And Human Services | Recombinant virus expressing carcinoembryonic antigen and methods of use thereof |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| DK0606217T4 (da) | 1991-06-27 | 2009-03-30 | Bristol Myers Squibb Co | CTL4-receptor, fusionsproteiner indeholdende den samt anvendelse deraf |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
| US6482919B2 (en) | 1993-02-01 | 2002-11-19 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US6361770B1 (en) | 1994-09-23 | 2002-03-26 | University Of British Columbia | Method of enhancing expression of MHC class I molecules bearing endogenous peptides |
| JP3907698B2 (ja) | 1994-10-03 | 2007-04-18 | アメリカ合衆国 | 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物 |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5767071A (en) | 1995-06-07 | 1998-06-16 | Ixsys Incorporated | Sevenmer cyclic peptide inhibitors of diseases involving αv β3 |
| US5780426A (en) | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US6165476A (en) | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| GB9801930D0 (en) | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US20040063094A1 (en) | 1998-05-20 | 2004-04-01 | Biovex Limited | Mutant herpes simplex viruses and uses thereof |
| GB2337755B (en) | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
| DK2272859T3 (en) | 1998-08-07 | 2015-01-19 | Univ Washington | Immunological herpes simplex virus antigens and methods for their use |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| US8624010B1 (en) | 1999-02-03 | 2014-01-07 | Steven K. Yoshinaga | Nucleic acids encoding B7RP1 |
| US6365619B1 (en) | 1999-07-22 | 2002-04-02 | Novartis Ag | Treatment of arteriosclerosis |
| DE60039766D1 (de) | 1999-08-09 | 2008-09-18 | Targeted Genetics Corp | Terologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen |
| ATE366814T1 (de) | 1999-09-21 | 2007-08-15 | Genetics Inst Llc | Gl50 moleküle, sowie verwendungen derselben |
| US7329728B1 (en) | 1999-10-25 | 2008-02-12 | The Scripps Research Institute | Ligand activated transcriptional regulator proteins |
| JP4723782B2 (ja) | 2000-01-03 | 2011-07-13 | ティーアール アソシエイツ，エル．エル．シー． | 新規なキメラ蛋白質及び該蛋白質の使用方法 |
| KR100802403B1 (ko) | 2000-01-21 | 2008-02-13 | 바이오벡스 리미티드 | 바이러스 주 |
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| EP3029062A1 (en) * | 2000-05-26 | 2016-06-08 | Bristol-Myers Squibb Company | Soluble ctla4 mutant molecules and uses thereof |
| US7183376B2 (en) | 2000-06-23 | 2007-02-27 | Maxygen, Inc. | Variant B7 co-stimulatory molecules |
| JP2004513878A (ja) | 2000-06-23 | 2004-05-13 | マキシジェン， インコーポレイテッド | 新規同時刺激分子 |
| CA2413190C (en) | 2000-07-03 | 2009-04-07 | Bristol-Myers Squibb Company | Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| US7011972B2 (en) | 2000-07-18 | 2006-03-14 | The Scripps Research Institute | Fusion polypeptide comprising two ligand binding domains |
| ATE390931T1 (de) | 2001-05-23 | 2008-04-15 | Bristol Myers Squibb Co | Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen |
| KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
| US6871421B2 (en) | 2001-09-21 | 2005-03-29 | Daniel R. Potter | Footwear with bladder type stabilizer |
| CN1304559C (zh) | 2001-10-09 | 2007-03-14 | 杭州康科生物技术有限公司 | 表达热休克蛋白的溶瘤微生物及其应用 |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| AU2002352913B2 (en) | 2001-11-30 | 2008-05-29 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Peptide agonists of prostate-specific antigen, and uses therefor |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| PT1572744E (pt) | 2002-12-16 | 2010-09-07 | Genentech Inc | Variantes de imunoglobulina e utilizações destas |
| KR101088223B1 (ko) | 2002-12-23 | 2011-11-30 | 브리스톨-마이어스 스큅 컴퍼니 | 단백질 생산을 위한 포유류 세포 배양 방법에서의 생산물품질 향상 |
| EP1591527B1 (en) | 2003-01-23 | 2015-08-26 | Ono Pharmaceutical Co., Ltd. | Substance specific to human pd-1 |
| SG179291A1 (en) | 2003-06-18 | 2012-04-27 | Genelux Corp | Modified recombinant vaccinia viruses and other microorganisms, uses thereof |
| EP1670499A4 (en) | 2003-08-04 | 2009-07-22 | Bristol Myers Squibb Co | METHODS OF TREATING A CARDIOVASCULAR DISEASE USING A SOLUBLE CTLA4 MOLECULE |
| WO2005063816A2 (en) | 2003-12-19 | 2005-07-14 | Genentech, Inc. | Monovalent antibody fragments useful as therapeutics |
| BR122019012028B1 (pt) | 2004-04-13 | 2023-09-26 | F. Hoffmann-La Roche Ag | Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição |
| BRPI0510674A (pt) | 2004-07-15 | 2007-12-26 | Xencor Inc | variantes fc otimizadas |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| EP1810979B1 (en) | 2004-09-22 | 2012-06-20 | Kyowa Hakko Kirin Co., Ltd. | STABILIZED HUMAN IgG4 ANTIBODIES |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| EP1819823A2 (en) | 2004-12-01 | 2007-08-22 | Bayer Schering Pharma Aktiengesellschaft | Generation of replication competent viruses for therapeutic use |
| KR20070107687A (ko) | 2004-12-31 | 2007-11-07 | 제넨테크, 인크. | Ｂｒ３과 결합하는 폴리펩티드, 및 그의 용도 |
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| LT1868635T (lt) | 2005-04-06 | 2017-07-10 | Bristol-Myers Squibb Company | Imuninių sutrikimų, susijusių su transplantato persodinimu, gydymo būdas tirpiomis mutantinėmis ctla4 molekulėmis |
| JP2007103345A (ja) | 2005-09-07 | 2007-04-19 | Toyota Motor Corp | チューブ状固体高分子型燃料電池、及びチューブ状固体高分子型燃料電池の製造方法 |
| US7655439B2 (en) | 2005-09-09 | 2010-02-02 | Zymogenetics, Inc. | Trimerizing polypeptides |
| GB0522476D0 (en) | 2005-11-03 | 2005-12-14 | Biovex Ltd | Oncolytic herpes virus vectors |
| TWI423986B (zh) | 2005-12-20 | 2014-01-21 | 必治妥美雅史谷比公司 | 組合物及製造組合物之方法 |
| EP2426142A3 (en) | 2006-10-16 | 2012-06-13 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
| GB0620934D0 (en) * | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
| WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
| PT2856876T (pt) | 2007-03-30 | 2018-03-28 | Memorial Sloan Kettering Cancer Center | Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos |
| JP5213075B2 (ja) | 2007-06-15 | 2013-06-19 | ジェネラックス・コーポレイション | 腫瘍の画像化および／または処置のための微生物 |
| EP2514762B1 (en) | 2007-07-13 | 2015-04-08 | The Johns Hopkins University | B7-DC variants |
| CA2693623A1 (en) | 2007-07-18 | 2009-01-22 | Genelux Corporation | Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy |
| WO2009054996A2 (en) | 2007-10-25 | 2009-04-30 | Genelux Corporation | Systems and methods for viral therapy |
| DK2222697T3 (da) | 2007-11-01 | 2013-03-11 | Perseid Therapeutics Llc | Immunsuppressive polypeptider og nukleinsyrer |
| WO2009067800A1 (en) | 2007-11-27 | 2009-06-04 | Viventia Biotech Inc. | Antibodies against a cancer-associated epitope of variant nfkbib and uses thereof |
| RS56844B1 (sr) | 2007-12-11 | 2018-04-30 | Univ North Carolina Chapel Hill | Retrovirusni vektori sa modifikovanim polipurinskim nizom |
| MX2010011088A (es) | 2008-04-09 | 2010-11-05 | Genentech Inc | Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad. |
| US7915222B2 (en) | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
| EP2300023A2 (en) | 2008-05-16 | 2011-03-30 | Genelux Corporation | Microorganisms for preventing and treating neoplasms accompanying cellular therapy |
| WO2010059253A2 (en) | 2008-11-24 | 2010-05-27 | Massachusets Institute Of Technology | Methods and compositions for localized agent delivery |
| MX2011008190A (es) | 2009-02-04 | 2011-10-06 | Univ Texas | Direccionamiento dual de mir-208 y mir-499 en el tratamiento de trastornos cardiacos. |
| EP2283810A1 (en) | 2009-07-16 | 2011-02-16 | University College Cork-National University of Ireland, Cork | Orally administered bacteria as vehicles for systemic delivery of agents |
| US20150359909A1 (en) | 2009-07-16 | 2015-12-17 | University College Cork-National University Of Ireland, Cork | Orally administered bacteria as vehicles for systemic delivery of agents |
| JP5883384B2 (ja) | 2009-08-13 | 2016-03-15 | ザ ジョンズ ホプキンス ユニバーシティー | 免疫機能を調節する方法 |
| CA2775761C (en) | 2009-09-30 | 2018-08-28 | Memorial Sloan-Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
| US9540426B2 (en) | 2009-10-06 | 2017-01-10 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| US9133436B2 (en) | 2010-02-04 | 2015-09-15 | The Trustees Of The University Of Pennsylvania | ICOS critically regulates the expansion and function of inflammatory human Th17 cells |
| PL2536745T3 (pl) | 2010-02-19 | 2017-01-31 | Xencor, Inc. | Nowe immunoadhezyny CTLA4-IG |
| IL300733B1 (en) | 2010-03-05 | 2025-10-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeted for immune modulation |
| WO2011113019A2 (en) | 2010-03-12 | 2011-09-15 | Abbott Biotherapeutics Corp. | Ctla4 proteins and their uses |
| DK2560683T4 (da) | 2010-04-23 | 2022-08-29 | Hoffmann La Roche | Fremstilling af heteromultimeriske proteiner |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| AU2012207356A1 (en) | 2011-01-18 | 2013-08-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| MX348071B (es) | 2011-03-16 | 2017-05-26 | Amgen Inc | Variantes de fc. |
| WO2012141984A1 (en) | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| WO2012149364A1 (en) | 2011-04-28 | 2012-11-01 | Diamond Don J | Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy |
| CN102836441B (zh) | 2011-06-24 | 2019-06-11 | 台北荣民总医院 | 于感染性与恶性疾病的治疗中提升免疫反应的方法 |
| EP2726101B1 (en) | 2011-06-30 | 2018-08-08 | Genzyme Corporation | Inhibitors of t-cell activation |
| SG11201400527XA (en) | 2011-09-16 | 2014-04-28 | Univ Pennsylvania | Rna engineered t cells for the treatment of cancer |
| WO2013041029A1 (en) * | 2011-09-23 | 2013-03-28 | Igenimed Pharmaceuticals Inc. | Novel soluble ctla4 variants |
| US8956619B2 (en) | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
| CN107496932A (zh) | 2012-02-27 | 2017-12-22 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
| US9758566B2 (en) | 2012-03-29 | 2017-09-12 | The General Hospital Corporation | Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4) |
| SG10201609447XA (en) * | 2012-05-11 | 2017-01-27 | Medimmune Llc | Ctla-4 variants |
| US20130319861A1 (en) | 2012-05-30 | 2013-12-05 | Berkeley Lights, Inc. | Outputting A Droplet Of Liquid Medium From A Device For Processing Micro-Objects In The Medium |
| WO2013184912A2 (en) | 2012-06-06 | 2013-12-12 | Oncomed Pharmaceuticals, Inc. | Binding agents that modulate the hippo pathway and uses thereof |
| CN113138279A (zh) | 2012-06-27 | 2021-07-20 | 法姆制药有限责任公司 | 融合蛋白组合物的应用 |
| JP5857896B2 (ja) | 2012-07-06 | 2016-02-10 | 東京エレクトロン株式会社 | 成膜装置の運転方法及び成膜装置 |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| US9327014B2 (en) | 2012-12-04 | 2016-05-03 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| US9944689B2 (en) | 2013-03-07 | 2018-04-17 | The General Hospital Corporation | Human CTLA4 mutants and use thereof |
| US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| MX2015011670A (es) | 2013-03-15 | 2016-03-31 | Biogen Ma Inc | Tratamiento y prevencion de lesion renal aguda usando anticuerpos anti-alfa v beta 5. |
| WO2014198002A1 (en) | 2013-06-14 | 2014-12-18 | Ottawa Hospital Research Institute | A bacterium producing an interferon binding protein and uses thereof |
| WO2014207748A1 (en) | 2013-06-27 | 2014-12-31 | Alexander Biro | Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease |
| GB201311475D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Polypeptides |
| DK3021869T3 (da) | 2013-07-16 | 2020-09-21 | Hoffmann La Roche | Fremgangsmåder til behandling af cancer ved anvendelse af PD-1-aksebindende antagonister og TIGIT-hæmmere |
| BR112016016416A2 (pt) | 2014-01-15 | 2017-10-03 | Hoffmann La Roche | VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS |
| KR20160113268A (ko) | 2014-01-28 | 2016-09-28 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 이기능 융합단백질,이의 제조방법 및 용도 |
| ES2792849T3 (es) | 2014-02-10 | 2020-11-12 | Univ Emory | Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer |
| KR20160145789A (ko) | 2014-04-25 | 2016-12-20 | 브리스톨-마이어스 스큅 컴퍼니 | 초기 ra를 갖는 대상체에서의 무약물 완화를 달성하기 위한 ctla4 화합물의 용도 |
| US10562954B2 (en) | 2014-05-12 | 2020-02-18 | Shanghai Kanda Biotechnology Co., Ltd. | Fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof |
| KR20150135148A (ko) | 2014-05-23 | 2015-12-02 | 주식회사 제넥신 | Pd-l1 융합 단백질 및 이의 용도 |
| KR20170032373A (ko) | 2014-07-15 | 2017-03-22 | 이뮨 디자인 코포레이션 | Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법 |
| WO2016011264A1 (en) | 2014-07-16 | 2016-01-21 | Genentech, Inc. | Methods of treating cancer using tigit inhibitors and anti-cancer agents |
| JP6895374B2 (ja) | 2014-07-16 | 2021-06-30 | トランジェーヌＴｒａｎｓｇｅｎｅ | 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス |
| EP3177640B1 (en) | 2014-08-08 | 2020-05-06 | The Board of Trustees of the Leland Stanford Junior University | High affinity pd-1 agents and methods of use |
| SG10201901735XA (en) | 2014-09-03 | 2019-03-28 | Bavarian Nordic As | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine |
| US20160145344A1 (en) | 2014-10-20 | 2016-05-26 | University Of Southern California | Murine and human innate lymphoid cells and lung inflammation |
| AU2015343048A1 (en) | 2014-11-06 | 2017-05-18 | Children's Research Institute, Children's National Medical Center | Immunotherapeutics for cancer and autoimmune diseases |
| EP3020816A1 (en) | 2014-11-11 | 2016-05-18 | University College Cork | Bacterial mediated gene therapy |
| WO2016118577A1 (en) | 2015-01-22 | 2016-07-28 | Medimmune, Llc | Thymosin-beta-four fusion proteins |
| CN107708725A (zh) | 2015-04-02 | 2018-02-16 | 坎库雷有限公司 | 用于引发免疫应答的剂和组合物 |
| EP3283508B1 (en) | 2015-04-17 | 2021-03-17 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| CN116333138A (zh) | 2015-07-30 | 2023-06-27 | 宏观基因有限公司 | Pd-1结合分子和其使用方法 |
| US20180221508A1 (en) | 2015-07-31 | 2018-08-09 | Tarveda Therapeutics, Inc. | Compositions and methods for immunomodulation |
| EA201890729A1 (ru) * | 2015-09-14 | 2018-09-28 | Элпайн Имьюн Сайнс, Инк. | Настраиваемые варианты доменов суперсемейства иммуноглобулинов и терапия сконструированными клетками |
| US11684656B2 (en) | 2015-11-04 | 2023-06-27 | Taipei Veterans General Hospital | Combination therapy for malignant diseases |
| TW202208440A (zh) | 2015-12-14 | 2022-03-01 | 美商宏觀基因股份有限公司 | 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法 |
| EP3443000B1 (en) | 2016-04-15 | 2025-11-12 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| KR102824067B1 (ko) | 2016-04-15 | 2025-06-23 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos 리간드 변이체 면역조절 단백질 및 그의 용도 |
| CA3022331A1 (en) | 2016-05-18 | 2017-11-23 | Albert Einstein College Of Medicine, Inc. | Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof |
| CN110088127A (zh) | 2016-07-28 | 2019-08-02 | 高山免疫科学股份有限公司 | Cd155变体免疫调节蛋白及其用途 |
| US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
| CN110214148A (zh) | 2016-10-14 | 2019-09-06 | Xencor股份有限公司 | 含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白 |
| AU2017345764A1 (en) | 2016-10-20 | 2019-05-02 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| CA3054068A1 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| LT3596116T (lt) | 2017-03-16 | 2023-11-10 | Alpine Immune Sciences, Inc. | Imunomoduliacinių baltymų pd-l1 variantai ir jų naudojimo būdai |
| CN110809581A (zh) | 2017-03-16 | 2020-02-18 | 高山免疫科学股份有限公司 | Pd-l2变体免疫调节蛋白及其用途 |
| KR102813968B1 (ko) | 2017-10-10 | 2025-05-29 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| MX2020004540A (es) | 2017-10-18 | 2020-08-03 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras de ligando icos variante y composiciones y metodos relacionados. |
| EP3735417A1 (en) | 2018-01-03 | 2020-11-11 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| WO2020047329A1 (en) | 2018-08-29 | 2020-03-05 | Shattuck Labs, Inc. | Chimeric proteins comprising extracellular domains and uses thereof |
| CN113727998A (zh) | 2018-11-30 | 2021-11-30 | 高山免疫科学股份有限公司 | Cd86变体免疫调节蛋白及其用途 |
| CN115812077A (zh) | 2020-05-08 | 2023-03-17 | 高山免疫科学股份有限公司 | April和baff抑制性免疫调节蛋白及其使用方法 |
-
2018
- 2018-10-09 KR KR1020237003305A patent/KR102813968B1/ko active Active
- 2018-10-09 EP EP18793148.0A patent/EP3694870A1/en active Pending
- 2018-10-09 WO PCT/US2018/055095 patent/WO2019074983A1/en not_active Ceased
- 2018-10-09 KR KR1020257001803A patent/KR20250020681A/ko active Pending
- 2018-10-09 MA MA050360A patent/MA50360A/fr unknown
- 2018-10-09 US US16/755,072 patent/US11753458B2/en active Active
- 2018-10-09 CN CN201880077176.3A patent/CN111801347A/zh active Pending
- 2018-10-09 CA CA3077509A patent/CA3077509A1/en active Pending
- 2018-10-09 EP EP24180271.9A patent/EP4442268A3/en active Pending
- 2018-10-09 CN CN202510950234.0A patent/CN121021670A/zh active Pending
- 2018-10-09 JP JP2020520253A patent/JP7749319B2/ja active Active
- 2018-10-09 KR KR1020207012697A patent/KR102758545B1/ko active Active
- 2018-10-09 EP EP23153416.5A patent/EP4219540A3/en not_active Withdrawn
- 2018-10-09 CA CA3198255A patent/CA3198255A1/en active Pending
-
2023
- 2023-01-30 US US18/161,799 patent/US20230250152A1/en active Pending
- 2023-06-26 JP JP2023104092A patent/JP2023138962A/ja active Pending
- 2023-07-20 US US18/355,539 patent/US12358969B2/en active Active
-
2025
- 2025-06-26 US US19/250,472 patent/US20250320272A1/en active Pending
- 2025-07-10 JP JP2025116732A patent/JP2025148471A/ja active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11274140B2 (en) | 2020-05-08 | 2022-03-15 | Alpine Immune Sciences, Inc. | APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof |
| US12202882B2 (en) | 2020-05-08 | 2025-01-21 | Alpine Immune Sciences, Inc. | APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof |
| US12304943B2 (en) | 2020-05-08 | 2025-05-20 | Alpine Immune Sciences, Inc. | April and BAFF inhibitory immunomodulatory proteins and methods of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111801347A (zh) | 2020-10-20 |
| JP2020536552A (ja) | 2020-12-17 |
| KR102813968B1 (ko) | 2025-05-29 |
| EP4219540A3 (en) | 2023-12-06 |
| EP4442268A2 (en) | 2024-10-09 |
| US20230250152A1 (en) | 2023-08-10 |
| US20240158463A1 (en) | 2024-05-16 |
| KR20200074137A (ko) | 2020-06-24 |
| CA3198255A1 (en) | 2019-04-18 |
| KR102758545B1 (ko) | 2025-01-23 |
| JP2025148471A (ja) | 2025-10-07 |
| US20250320272A1 (en) | 2025-10-16 |
| US11753458B2 (en) | 2023-09-12 |
| EP4219540A2 (en) | 2023-08-02 |
| EP3694870A1 (en) | 2020-08-19 |
| US12358969B2 (en) | 2025-07-15 |
| JP7749319B2 (ja) | 2025-10-06 |
| US20200308249A1 (en) | 2020-10-01 |
| MA50360A (fr) | 2020-08-19 |
| CN121021670A (zh) | 2025-11-28 |
| WO2019074983A1 (en) | 2019-04-18 |
| EP4442268A3 (en) | 2025-04-02 |
| KR20230020022A (ko) | 2023-02-09 |
| KR20250020681A (ko) | 2025-02-11 |
| JP2023138962A (ja) | 2023-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11498967B2 (en) | CD80 variant immunomodulatory proteins and uses thereof | |
| US12358969B2 (en) | CTLA-4 variant immunomodulatory proteins and uses thereof | |
| US20250163127A1 (en) | Multi-domain immunomodulatory proteins and methods of use thereof | |
| US11834490B2 (en) | CD112 variant immunomodulatory proteins and uses thereof | |
| EP3697810B1 (en) | Variant icos ligand immunomodulatory proteins and related compositions and methods | |
| CA3019199A1 (en) | Icos ligand variant immunomodulatory proteins and uses thereof | |
| CA3032120A1 (en) | Cd155 variant immunomodulatory proteins and uses thereof | |
| JP2020536552A5 (enExample) | ||
| HK40106341A (en) | Pd-l1 variant immunomodulatory proteins and uses thereof | |
| HK40031114A (en) | Ctla-4 variant immunomodulatory proteins and uses thereof | |
| EA044356B1 (ru) | Вариантные иммуномодулирующие белки лиганда icos и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220412 |
|
| EEER | Examination request |
Effective date: 20220412 |
|
| EEER | Examination request |
Effective date: 20220412 |
|
| EEER | Examination request |
Effective date: 20220412 |
|
| EEER | Examination request |
Effective date: 20220412 |
|
| EEER | Examination request |
Effective date: 20220412 |
|
| EEER | Examination request |
Effective date: 20220412 |
|
| EEER | Examination request |
Effective date: 20220412 |
|
| EEER | Examination request |
Effective date: 20220412 |
|
| EEER | Examination request |
Effective date: 20220412 |
|
| EEER | Examination request |
Effective date: 20220412 |
|
| EEER | Examination request |
Effective date: 20220412 |
|
| EEER | Examination request |
Effective date: 20220412 |
|
| EEER | Examination request |
Effective date: 20220412 |
|
| EEER | Examination request |
Effective date: 20220412 |
|
| EEER | Examination request |
Effective date: 20220412 |
|
| EEER | Examination request |
Effective date: 20220412 |
|
| EEER | Examination request |
Effective date: 20220412 |